期刊文献+

68Ga—DOTATATE的合成及动物实验研究 被引量:6

Synthesis and in vivo evaluation of 68Ga-DOTATATE in mice
原文传递
导出
摘要 目的研究金属核素多功能模块自动化及手工合成68Ga.1,4,7,10-四氮杂十二烷-N,N,N,N-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸墙-奥曲肽(68Ga—DOTATATE)的可行性,并探讨其生物学分布及肿瘤显像特点。方法采用强阳离子交换(SCX)柱金属核素多功能模块自动化及手工方法合成68Ga—DOTATATE,并对产品注射液进行质量控制。取ICR小鼠30只,分为5组,分别于注射68Ga—DOTATATE后10、30、60、120和240min处死,取各脏器、称质量并测定放射性计数,计算放射性摄取值(%ID/g),观察生物学分布。对荷AR42J大鼠胰腺外分泌腺肿瘤裸鼠注射68Ga—DOTATATE后行microPET显像,观察肿瘤对68Ga.DOTATATE的摄取情况。结果金属核素多功能模块自动化与手工合成2种方法均能顺利合成68Ga—DOTATATE。产品均为无色澄明溶液,pH值为6.5±0.1,放化纯均大于99%,室温放置4h仍大于99%。自动化合成需时约30min,放化产率为(51.8±3.2)%(时间衰减校正);手工合成需时约20min,标记率大于99%。14d细菌培养及细菌内毒素检查结果均符合规定。ICR小鼠体内生物学分布结果显示,肾脏为药物排泄器官,肝、脾、胰腺和肾上腺摄取较高,肌肉软组织摄取低;药物的血液清除陕,10rain为(4.41±0.81)%ID/g,1h时仅为(O.78±0.32)%ID/g。荷AR42J瘤裸鼠microPET显像示,肿瘤组织对68Ga.DOTATATE明显高摄取,T/NT分别为2.01±0.29(10min)、6.74±2.90(30min)和4.46+2.05(60min)。结论68Ga—DOTATATE合成工艺简单、质控合格、动物实验结果良好,是一种有潜在应用前景的新型生长抑素类特异性正电子显像剂。 Objective To synthesize 68Ga-1,4,7,10-tetraazacyclododecane-N,N',N',N'-tetraacetic acid-D-Phel-Tyr3-ThrS-octreotide (68 Ga-DOTATATE) manually and automatically, validate its qualities in vitro, and evaluate its biodistribution in ICR mice and the microPET imaging in nude mice bearing pancreatic AR42J tumor. Methods 68 Ga-DOTATATE was synthesized by automatic method using commercial metal isotope multifunctional module with strong cation exchange (SCX) column and by manual method. Both the products were measured for quality control. For the biodistribution study 5 groups of ICR mice were injected with 68Ga-DOTATATE( 1.11 MBq) and executed at 10, 30, 60, 120 and 240 rain postinjection, respectively. The organs were weighted, and %ID/g was calculated. Nude mice bearing pancreatic AR42J tumor were intravenously injected with 3.7 MBq 68Ga-DOTATATE, and then microPET imaging was acquired at 10, 30, 60, 120, 18 and 240 rain. Results 6SGa-DOTATATE could be successfully synthesized by the automatic and manual methods. Both the product injections were colorless and clear. The pH value was 6.5±0.1. For the products obtained from the two methods, the radiochemical purities were over 99%,and the products were stable for 4 h at room temperature. For the automatic method, 6s Ga-DOTATATE was synthesized within 30 rain and with the radiochemical yield of (51.8±3.2)% (time decay corrected) . For the manual method, the time used for the synthesis was 20 rain, and the labeling yield was over 99%. Three batches of the products were aseptic and pyrogen-free. In ICR mice, 6SGa-DOTATATE was excreted by the kidney, and showed relatively high accumulation in the liver, spleen, pancreas and adrenal glands, while lower in the bone and soft tissue. The clearance from blood was fast with (4.41±0.81) %ID/g at 10 rain postinjection and (0.78±0.32) % ID/g at 1 h. MicroPET imaging showed increased uptake of 6SGa- DOTATATE in the tumor tissues, and T/NT were 2.01±0.29( 10 min), 6.74±2.90(30 min) and 4.46± 2. 05 (60 min), respectively. Conclusions 6s Ga-DOTATATE could be successfully synthesized manually and automatically. The products reach to the specification of radioactive drugs and could be used as an at- tractive positron emitting radiotracer for detection of the somatostatin receptor-positive tumors.
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2014年第6期490-494,共5页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 国家自然科学基金(81071189,81171369)
关键词 DOTATATE 同位素标记 镓放射性同位素 化学合成 体层摄影术 发射型计算机 小鼠 DOTATATE Isotope labeling Gallium radioisotopes Chemical synthesis Tomography, emission-computed Mice, nude
  • 相关文献

参考文献3

二级参考文献126

  • 1王峰,方纬,季顺东,孟庆乐,立彦,樊克武,王自正.锝标突触结合蛋白Ⅰ C2A片段探测肺癌凋亡的实验研究[J].中华肿瘤杂志,2007,29(5):351-354. 被引量:7
  • 2van Eeden S, Offerhaus GJ. Historical, current and future perspectives on gastrointestinal and pancreatic endocrine tumors. Virchows Arch, 2006, 448 (1): 1-6.
  • 3Simon P, Spilcke-Liss E, Wallaschofski H. Endocrine tumors of the pancreas. Endocrinol Metab Clin North Am, 2006, 35 (2): 431-447, xii.
  • 4Oberg K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol, 2005, 17 (4): 386-391.
  • 5Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab, 2007, 21 (1): 69-85.
  • 6Gotthardt M, Dijkgraaf I, Boerman OC, et al. Nuclear medicine imaging and therapy of neuroendocrine tumours. Cancer Imaging, 2006, 6: S178-S184.
  • 7Decristoforo C, Mather S J, Cholewinski W, et al. 99mTc- EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med, 2000, 27 (9): 1318-1325.
  • 8Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med, 2003, 44 (5): 708-716.
  • 9de Herder WW, Holland L J, van der Lely A J, et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer, 2003, 10 (4): 451-458.
  • 10Schillaci O, Spanu A, Scopinaro F, et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med, 2003, 44 (3): 359-368.

共引文献29

同被引文献11

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部